person · Reporting owner

Arjona Ferreira Juan Camilo

Disclosed activity across 2 companies

Tapewire entity: 24130
SEC CIK: 0001714080

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Organon & Co.OGN · Entity 4115	Head of R&D & CMO	August 11, 2026	August 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Organon & Co.

Report date August 11, 2026 · Filed August 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	37,432.477	Ending reported balance After 2026-08-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-11 · Exercise / conversion · Acquired 11,519 · Balance 41,566.477 Row 2 · 2026-08-11 · Tax withholding · Disposed 4,134 · Balance 37,432.477
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-08-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-11 · Exercise / conversion · Acquired 11,519 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the third and final vesting occurring on August 11, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the third and final vesting occurring on August 11, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Myovant Sciences Ltd.

Report date March 10, 2023 · Filed March 10, 2023

Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Ending reported balance After 2023-03-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-03-10 · Disposition to issuer · Disposed 86,602 · Balance 160,082 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"). Row 2 · 2023-03-10 · Disposition to issuer · Disposed 160,082 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F3: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2027-08-14	Direct	Reported balance After 2023-03-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-10 · Disposition to issuer · Disposed 155,300 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2028-04-15	Direct	Reported balance After 2023-03-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-03-10 · Disposition to issuer · Disposed 63,717 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2029-04-04	Direct	Reported balance After 2023-03-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-03-10 · Disposition to issuer · Disposed 65,863 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F6: One-fourth of the options vested on April 5, 2020, and one-sixteenth of the options vest each quarter thereafter.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2030-04-02	Direct	Reported balance After 2023-03-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-03-10 · Disposition to issuer · Disposed 134,464 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F7: One-fourth of the options vested on April 3, 2021, and one-sixteenth of the options vest each quarter thereafter.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.88 · Expires 2031-04-14	Direct	Reported balance After 2023-03-10 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-03-10 · Disposition to issuer · Disposed 79,472 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F8: One-fourth of the options vested on April 15, 2022, and one-sixteenth of the options vest each quarter thereafter.
Performance Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-03-10 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-03-10 · Disposition to issuer · Disposed 103,703 · Balance 0 F9: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

Filing footnotes · ownership attribution and instrument terms

F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F2: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration").

F3: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time.

F4: These options are fully vested.

F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

F6: One-fourth of the options vested on April 5, 2020, and one-sixteenth of the options vest each quarter thereafter.

F7: One-fourth of the options vested on April 3, 2021, and one-sixteenth of the options vest each quarter thereafter.

F8: One-fourth of the options vested on April 15, 2022, and one-sixteenth of the options vest each quarter thereafter.

F9: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 11, 2026 Filed Aug 12, 2026 17:01 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	11,519	$0.00	$0.00	Disclosure SEC source: 0001628280-26-056061 · wk-form4_1786554094.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the third and final vesting occurring on August 11, 2026. F2 · derivative.expiration_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the third and final vesting occurring on August 11, 2026. Read SEC document
August 11, 2026 Filed Aug 12, 2026 17:01 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	4,134	$13.62	$56,305.08	Disclosure SEC source: 0001628280-26-056061 · wk-form4_1786554094.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,432.477 Read SEC document
August 11, 2026 Filed Aug 12, 2026 17:01 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	11,519	$0.00	$0.00	Disclosure SEC source: 0001628280-26-056061 · wk-form4_1786554094.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,566.477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:18 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	13,431	$0.00	$0.00	Disclosure SEC source: 0001628280-26-023188 · wk-form4_1775161114.xml · derivative · entry 4 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,864 Underlying: Common Stock · 13,431 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 40,295 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F4 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 40,295 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:18 UTC	Organon & Co. OGN · Entity 4115	GrantRestricted Stock Units · Derivative	200,333	$0.00	$0.00	Disclosure SEC source: 0001628280-26-023188 · wk-form4_1775161114.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,333 Underlying: Common Stock · 200,333 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:18 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	4,820	$5.70	$27,474.00	Disclosure SEC source: 0001628280-26-023188 · wk-form4_1775161114.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,047.477 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document
March 31, 2026 Filed Apr 2, 2026 20:18 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	13,431	$0.00	$0.00	Disclosure SEC source: 0001628280-26-023188 · wk-form4_1775161114.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,867.477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 29, 2026 Filed Mar 31, 2026 20:09 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	8,865	$0.00	$0.00	Disclosure SEC source: 0001628280-26-022387 · wk-form4_1774987760.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,865 Underlying: Common Stock · 8,865 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F5 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document
March 29, 2026 Filed Mar 31, 2026 20:09 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	3,181	$5.84	$18,577.04	Disclosure SEC source: 0001628280-26-022387 · wk-form4_1774987760.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,436.477 F2 · price: This price is the closing market price of Organon common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. F3 · balance_after: Includes the addition of 708.122 shares of Organon common stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document
March 29, 2026 Filed Mar 31, 2026 20:09 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	8,865	$0.00	$0.00	Disclosure SEC source: 0001628280-26-022387 · wk-form4_1774987760.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,909.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The total number of shares reported as beneficially owned has been reduced to reflect 13,872 shares of Organon & Co. ("Organon") common stock transferred pursuant to an exemption under Exchange Act Rule 16a-12. Read SEC document
November 07, 2025 Filed Nov 10, 2025 21:14 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	6,446	$0.00	$0.00	Disclosure SEC source: 0001628280-25-051052 · wk-form4_1762809245.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,447 Underlying: Common Stock · 6,446 shares Expires 2026-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three installments: 6,446 shares on November 7 2024; 6,446 shares on November 7, 2025; and 6,447 shares on November 7, 2026. Read SEC document
November 07, 2025 Filed Nov 10, 2025 21:14 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	2,307	$6.71	$15,479.97	Disclosure SEC source: 0001628280-25-051052 · wk-form4_1762809245.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,916.355 Read SEC document
November 07, 2025 Filed Nov 10, 2025 21:14 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	6,446	$0.00	$0.00	Disclosure SEC source: 0001628280-25-051052 · wk-form4_1762809245.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,223.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 11, 2025 Filed Aug 12, 2025 20:05 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	11,519	$0.00	$0.00	Disclosure SEC source: 0001821825-25-000068 · wk-form4_1755029130.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,519 Underlying: Common Stock · 11,519 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon & Co. common stock in three equal installments with 11,519 shares having vested on August 11, 2025 and the third and final vesting to occur on August 11, 2026. Read SEC document
August 11, 2025 Filed Aug 12, 2025 20:05 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	4,122	$9.22	$38,004.84	Disclosure SEC source: 0001821825-25-000068 · wk-form4_1755029130.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,777.355 Read SEC document
August 11, 2025 Filed Aug 12, 2025 20:05 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	11,519	$0.00	$0.00	Disclosure SEC source: 0001821825-25-000068 · wk-form4_1755029130.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,899.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:40 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	8,865	$0.00	$0.00	Disclosure SEC source: 0001821825-25-000012 · wk-form4_1743630049.xml · derivative · entry 5 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,730 Underlying: Common Stock · 8,865 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:40 UTC	Organon & Co. OGN · Entity 4115	GrantRestricted Stock Units · Derivative	40,295	$0.00	$0.00	Disclosure SEC source: 0001821825-25-000012 · wk-form4_1743630049.xml · derivative · entry 4 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,295 Underlying: Common Stock · 40,295 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:40 UTC	Organon & Co. OGN · Entity 4115	GrantStock Option (right to buy) · Derivative	198,019	$0.00 Strike: $14.89	$0.00	Disclosure SEC source: 0001821825-25-000012 · wk-form4_1743630049.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,019 Underlying: Common Stock · 198,019 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F3 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:40 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	3,172	$14.51	$46,025.72	Disclosure SEC source: 0001821825-25-000012 · wk-form4_1743630049.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,380.355 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:40 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	8,865	$0.00	$0.00	Disclosure SEC source: 0001821825-25-000012 · wk-form4_1743630049.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,552.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 07, 2024 Filed Nov 8, 2024 21:17 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	6,446	$0.00	$0.00	Disclosure SEC source: 0001821825-24-000110 · wk-form4_1731100655.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,893 Underlying: Common Stock · 6,446 shares Expires 2026-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Organon & Co. common stock. F2 · derivative.exercise_date: On November 7, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two installments on November 7, 2025 and November 7, 2026. Read SEC document
November 07, 2024 Filed Nov 8, 2024 21:17 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	2,300	$15.80	$36,340.00	Disclosure SEC source: 0001821825-24-000110 · wk-form4_1731100655.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,687.355 Read SEC document
November 07, 2024 Filed Nov 8, 2024 21:17 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	6,446	$0.00	$0.00	Disclosure SEC source: 0001821825-24-000110 · wk-form4_1731100655.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,987.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 11, 2024 Filed Aug 12, 2024 21:18 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionRestricted Stock Units · Derivative	11,519	$0.00	$0.00	Disclosure SEC source: 0001821825-24-000085 · wk-form4_1723497488.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,038 Underlying: Common Stock · 11,519 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon & Co. common stock in three equal installments of 11,519 shares on each of August 11, 2024; August 11, 2025; and August 11, 2026. Read SEC document
August 11, 2024 Filed Aug 12, 2024 21:18 UTC	Organon & Co. OGN · Entity 4115	Tax withholdingCommon Stock	3,991	$20.15	$80,418.65	Disclosure SEC source: 0001821825-24-000085 · wk-form4_1723497488.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,541.355 Read SEC document
August 11, 2024 Filed Aug 12, 2024 21:18 UTC	Organon & Co. OGN · Entity 4115	Exercise / conversionCommon Stock	11,519	$0.00	$0.00	Disclosure SEC source: 0001821825-24-000085 · wk-form4_1723497488.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,532.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 29, 2024 Filed Apr 16, 2024 10:23 UTC	Organon & Co. OGN · Entity 4115	GrantStock Option (right to buy) · Derivative	108,932	$0.00 Strike: $18.80	$0.00	Disclosure SEC source: 0001821825-24-000053 · wk-form4_1713263007.xml · derivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,932 Underlying: Common Stock · 108,932 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document
March 29, 2024 Filed Apr 16, 2024 10:23 UTC	Organon & Co. OGN · Entity 4115	GrantRestricted Stock Units · Derivative	26,595	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001821825-24-000053 · wk-form4_1713263007.xml · derivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,595 Underlying: Common Stock · 26,595 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:24 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerPerformance Stock Unit · Derivative	103,703	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-017715 · doc4.xml · derivative · entry 8 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 103,703 shares Expires not disclosed F9 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F9 · price: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. F9 · derivative.exercise_date: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. F9 · derivative.expiration_date: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:24 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	79,472	Not disclosed Strike: $17.88	Not disclosed	Disclosure SEC source: 0001209191-23-017715 · doc4.xml · derivative · entry 7 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 79,472 shares Expires 2031-04-14 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F8 · derivative.exercise_date: One-fourth of the options vested on April 15, 2022, and one-sixteenth of the options vest each quarter thereafter. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:24 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	134,464	Not disclosed Strike: $8.08	Not disclosed	Disclosure SEC source: 0001209191-23-017715 · doc4.xml · derivative · entry 6 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 134,464 shares Expires 2030-04-02 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F7 · derivative.exercise_date: One-fourth of the options vested on April 3, 2021, and one-sixteenth of the options vest each quarter thereafter. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:24 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	65,863	Not disclosed Strike: $7.78	Not disclosed	Disclosure SEC source: 0001209191-23-017715 · doc4.xml · derivative · entry 5 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 65,863 shares Expires 2029-04-04 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F6 · derivative.exercise_date: One-fourth of the options vested on April 5, 2020, and one-sixteenth of the options vest each quarter thereafter. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:24 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	63,717	Not disclosed Strike: $7.78	Not disclosed	Disclosure SEC source: 0001209191-23-017715 · doc4.xml · derivative · entry 4 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 63,717 shares Expires 2028-04-15 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:24 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	155,300	Not disclosed Strike: $7.78	Not disclosed	Disclosure SEC source: 0001209191-23-017715 · doc4.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 155,300 shares Expires 2027-08-14 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:24 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerCommon Shares	160,082	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-017715 · doc4.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F3 · price: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:24 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerCommon Shares	86,602	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-017715 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,082 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2 · price: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"). Read SEC document
January 18, 2023 Filed Jan 20, 2023 21:31 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	1,109	$26.89	$29,821.01	Disclosure SEC source: 0001209191-23-004277 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,684 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document
January 04, 2023 Filed Jan 5, 2023 22:21 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	2,251	$26.90	$60,551.90	Disclosure SEC source: 0001209191-23-001957 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,793 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document
October 18, 2022 Filed Oct 20, 2022 20:50 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	1,604	$25.20	$40,420.80	Disclosure SEC source: 0001209191-22-054194 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,044 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document
October 04, 2022 Filed Oct 6, 2022 20:28 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	2,738	$24.40	$66,807.20	Disclosure SEC source: 0001209191-22-052986 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,648 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document
July 18, 2022 Filed Jul 20, 2022 20:35 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	1,606	$12.87	$20,669.22	Disclosure SEC source: 0001209191-22-042686 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,386 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document
July 06, 2022 Filed Jul 8, 2022 20:09 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	2,755	$13.40	$36,917.00	Disclosure SEC source: 0001209191-22-041618 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,992 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2 · price: The shares were sold at prices ranging from $13.40 to $13.46. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 27, 2022 Filed Jun 1, 2022 20:20 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	1,382	$10.07	$13,916.74	Disclosure SEC source: 0001209191-22-033156 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,747 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document
April 19, 2022 Filed Apr 21, 2022 20:27 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	4,632	$10.45	$48,404.40	Disclosure SEC source: 0001209191-22-025173 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,129 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2 · price: The shares were sold at prices ranging from $10.45 to $10.47. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
April 15, 2022 Filed Apr 19, 2022 20:51 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	GrantCommon Shares	103,703	$0.00	$0.00	Disclosure SEC source: 0001209191-22-024787 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,761 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2023, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document
April 05, 2022 Filed Apr 7, 2022 20:16 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	1,922	$13.78	$26,485.16	Disclosure SEC source: 0001209191-22-023660 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,058 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2 · price: The shares were sold at prices ranging from $13.78 to $13.84. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:54 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	1,362	$13.35	$18,182.70	Disclosure SEC source: 0001209191-22-015559 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,980 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document
January 04, 2022 Filed Jan 6, 2022 21:21 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	2,271	$16.27	$36,949.17	Disclosure SEC source: 0001209191-22-002186 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,342 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document
November 29, 2021 Filed Dec 1, 2021 21:10 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	1,978	$19.30	$38,175.40	Disclosure SEC source: 0001209191-21-067262 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,613 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.